Published in Arch Neurol on October 13, 2008
Cladribine Tablets After Treatment With Natalizumab (CLADRINA) | NCT04178005
Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med (2011) 1.72
Integrin targeted therapeutics. Theranostics (2011) 1.36
Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs (2010) 1.31
Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology (2011) 1.24
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther (2014) 1.08
Targeting dendritic cells to treat multiple sclerosis. Nat Rev Neurol (2010) 1.02
Natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2009) 1.01
The immunopathophysiology of multiple sclerosis. Neurol Clin (2011) 0.99
Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis. J Immunol (2010) 0.99
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab. Front Immunol (2015) 0.98
Targeting cells in motion: migrating toward improved therapies. Eur J Immunol (2013) 0.98
Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One (2011) 0.97
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf (2012) 0.94
Emerging viral infections of the central nervous system: part 2. Arch Neurol (2009) 0.94
Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us? Front Cell Neurosci (2014) 0.90
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis. PLoS One (2012) 0.89
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. J Neuroinflammation (2012) 0.87
Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient. PLoS One (2012) 0.87
Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. MAbs (2010) 0.86
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol (2015) 0.85
Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One (2012) 0.85
Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141. PLoS Pathog (2015) 0.83
Dendritic cells in central nervous system autoimmunity. Semin Immunopathol (2016) 0.83
Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J (2014) 0.83
Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease. J Immunol (2016) 0.81
Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis. PLoS One (2014) 0.81
Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol (2012) 0.81
Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS. Adv Exp Med Biol (2012) 0.80
2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Clin Exp Immunol (2013) 0.79
Managing MS in a changing treatment landscape. J Neurol (2011) 0.79
Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol (2010) 0.79
Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One (2011) 0.78
Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis. Mediators Inflamm (2015) 0.78
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas (2014) 0.77
Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. Mult Scler Int (2015) 0.77
H(1)R expression by CD11B(+) cells is not required for susceptibility to experimental allergic encephalomyelitis. Cell Immunol (2012) 0.77
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord (2016) 0.75
CD4 cell response to interval therapy with natalizumab. Ann Clin Transl Neurol (2015) 0.75
Central nervous system immune surveillance: on natalizumab, dendritic cells, and dangerous immune privilege. Arch Neurol (2008) 0.75
Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats. Mol Med Rep (2016) 0.75
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol (2009) 6.96
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med (2006) 6.60
Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med (2000) 6.43
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 5.24
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
Varicella zoster virus, a cause of waxing and waning vasculitis: the New England Journal of Medicine case 5-1995 revisited. Neurology (1996) 4.02
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med (2007) 3.09
A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J Immunol (2002) 3.07
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96
T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med (2009) 2.96
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol (2007) 2.86
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol (2006) 2.70
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Factors that influence adherence with disease-modifying therapy in MS. J Neurol (2009) 2.67
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol (2006) 2.56
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55
γδ T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity (2010) 2.54
Concussion in sports. Guidelines for the prevention of catastrophic outcome. JAMA (1991) 2.53
Electron transport chain defects in Alzheimer's disease brain. Neurology (1994) 2.51
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data. Cytometry B Clin Cytom (2010) 2.38
How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol (2006) 2.38
An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage (2011) 2.31
Primary intraosseous meningioma. Case report. J Neurosurg (1995) 2.28
Toxic leukoencephalopathy. N Engl J Med (2001) 2.27
Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity (2004) 2.24
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol (2013) 2.22
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain (2011) 2.21
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Human herpesvirus 8 DNA in CNS lymphomas from patients with and without AIDS. Neurology (1998) 2.17
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol (2012) 2.15
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler (2011) 2.02
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol (2005) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest (2005) 1.95
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 1.92
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med (2013) 1.88
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol (2009) 1.85
Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol (2002) 1.83
Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol (2007) 1.82
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med (2011) 1.81
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin. Arch Pathol Lab Med (2003) 1.75
Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol (2012) 1.75
Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med (2011) 1.72
Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med (2006) 1.69
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol (2005) 1.63
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol (2004) 1.62
EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet (2010) 1.62
High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood (2004) 1.62
The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. Nat Neurosci (2009) 1.60
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol (2008) 1.59
Boxing-acute complications and late sequelae: from concussion to dementia. Dtsch Arztebl Int (2010) 1.59
Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics (2011) 1.57
Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol (2009) 1.55
Rapid correction of hyponatremia causes demyelination: relation to central pontine myelinolysis. Science (1981) 1.52
Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS. Neurology (2012) 1.51
Revised criteria for neuromyelitis optica--a new diagnostic standard? Nat Clin Pract Neurol (2007) 1.51
Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J (2011) 1.50
A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol (2005) 1.50
Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta (2010) 1.50
Proximal nerve root spinal hemangioblastomas: presentation of three cases, MR appearance, and literature review. Surg Neurol (2004) 1.49